Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARENA PHARMACEUTICALS INCARNA · Entity 94856 | Director | June 13, 2017 | June 14, 2017 |
| Lite Strategy, Inc.MEIP · Entity 7396 | Director | July 05, 2022 | July 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARENA PHARMACEUTICALS INC
Report date June 13, 2017 · Filed June 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2024-06-13 | Direct | 150,000 |
Reported balance
After 2017-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-13 · Grant · Acquired 150,000 · Balance 150,000 F1: The options vest over one year with one twelfth vesting on July 13, 2017, and the remainder of the shares vesting monthly over the following eleven months in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest over one year with one twelfth vesting on July 13, 2017, and the remainder of the shares vesting monthly over the following eleven months in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
Lite Strategy, Inc.
Report date July 05, 2022 · Filed July 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2032-07-05 | Direct | 87,500 |
Reported balance
After 2022-07-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-05 · Grant · Acquired 87,500 · Balance 87,500 F1: The options will vest in equal monthly installments over twelve months. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.95 · Expires 2031-07-01 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 50,000 F2: All of such options are presently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2025-07-28 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 20,000 F2: All of such options are presently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2026-07-29 | Direct | 40,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 40,000 F2: All of such options are presently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2027-07-06 | Direct | 40,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 40,000 F2: All of such options are presently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.28 · Expires 2028-07-12 | Direct | 40,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 40,000 F2: All of such options are presently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2029-07-01 | Direct | 40,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 40,000 F2: All of such options are presently exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.49 · Expires 2030-07-02 | Direct | 50,000 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 50,000 F2: All of such options are presently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in equal monthly installments over twelve months.
F2: All of such options are presently exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2022 Filed Jul 7, 2022 20:22 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 87,500 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0000899243-22-025699 · doc4.xml · derivative · entry 1 White Christine Anna · CIK 0001371859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2032-07-05 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 23:03 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001209191-21-045666 · doc4.xml · derivative · entry 1 White Christine Anna · CIK 0001371859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-07-01 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 17:40 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0000899243-20-018618 · doc4.xml · derivative · entry 1 White Christine Anna · CIK 0001371859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-07-02 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| September 06, 2019 Filed Sep 9, 2019 20:52 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | PurchaseCommon Stock | 15,000 | $1.74 | $26,074.50 |
DisclosureSEC source: 0001209191-19-048913 · doc4.xml · nonDerivative · entry 1 White Christine Anna · CIK 0001371859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The shares purchased by the reporting person are held through an Individual Retirement Account. F2 · price: The weighted average purchase price for the transaction reported was $1.7383, and the range of prices was between $1.725 and $1.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 19:34 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-19-040983 · doc4.xml · derivative · entry 1 White Christine Anna · CIK 0001371859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-07-01 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 21:30 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $4.28 | $0.00 |
DisclosureSEC source: 0001209191-18-042678 · doc4.xml · derivative · entry 1 White Christine Anna · CIK 0001371859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-07-12 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 18:56 UTC | Lite Strategy, Inc. MEIP · Entity 7396 | GrantOption to purchase shares of common stock · Derivative | 40,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001209191-17-044536 · doc4.xml · derivative · entry 1 White Christine Anna · CIK 0001371859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,730 Underlying: Common Stock par value $0.00000002 · 40,000 shares Expires 2027-07-06 F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months. F2 · balance_after: The total number of derivative securities reported in Column 9 includes previously awarded options, which were subject to the effect of a 1 for 6 reverse stock split, which was effective on December 18, 2012. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 19:47 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001209191-17-039982 · doc4.xml · derivative · entry 1 White Christine Anna · CIK 0001371859 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2024-06-13 F1 · derivative.exercise_date: The options vest over one year with one twelfth vesting on July 13, 2017, and the remainder of the shares vesting monthly over the following eleven months in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.